GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

GLP-1 RA use was linked to lower risks for myelodysplastic syndromes and myeloproliferative neoplasms compared with metformin. HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist ... study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA versus ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs ... to further assess and allow comparison of several GLP-1RA agents' impact on steady-state ...

Patients treated with EQW had a significantly greater reduction in A1c than those treated with exenetide b.i.d., (-1.9 vs -1.5% ... 6 study was designed to compare EQW head-to-head with liraglutide.

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like ...